PTC Therapeutics, Inc. with ticker code (PTCT) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 71 and 37 suggesting an average Analsyt target price of $55.50. Given that the stocks previous close was at $59.10 this is indicating there is a potential downside of -6.1%. Also worth taking note is the 50 day moving average now sits at $51.65 and the 200 moving average now moves to $46.97. The company has a market capitalization of 4.33B. The stock price for Iron Mountain Incorporated is 58.41 USD
The potential market cap would be $4,069,510,653 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 10.65 and a -16.81% return on assets.
PTC Therapeutics, Inc. is a science-driven, global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).
